Delivery Order SPE2DB24D2106-SPE2DB26FATWN
- Not listed
- The Defense Logistics Agency awarded a $3,559.66 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 ml syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,834.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Beyfortus 100 mg/mL syringes. The award was issued on October 20, 2025, with an ultimate completion date of October 21, 2025, with no set-aside designation applied. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, is serving...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $18,107.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, which runs through February 2, 2024, is for the supply of the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, holding a significant indefinite delivery contract (IDC) with the DLA under the...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $9,053.85 order is for BEYFORTUS 100 MG/ML SYRINGEML and is part of a larger, single-award indefinite delivery contract valued up to $4,999,999 through 2025. The contract enables DLA to issue delivery orders for a broad range of pharmaceutical items to fulfill the recurring medical supply needs of military...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $15,032.56 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract covers the procurement of BEYFORTUS 100 MG/ML SYRINGEML, with a completion date of September 30, 2024. This delivery order contract is part of a larger indefinite delivery contract (IDC) under the SPE2DB program, valued at up to $499,999,999, which allows...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,546.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of SYFOVRE 15 mg/0.1 mL vials. The award, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,347.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on September 28, 2025, falls under the DLA's larger Pharmaceutical Prime Vendor Fleet program and represents a continuation of the agency's pharmaceutical supply chain operations. The contract carries no set-aside designation, reflecting DMS...
- The Defense Logistics Agency awarded a delivery order valued at $16,332.86 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, on September 24, 2025. The contract calls for delivery of Beyfortus 50 mg/0.5 ml syringes and is structured as a firm fixed-price delivery order with an ultimate completion date of September 25, 2025. Performance will occur in Conshohocken, Pennsylvania. This award was made without a set-aside designation, allowing DMS Pharmaceutical...
- On September 9, 2025, the Defense Logistics Agency (DLA), operating under the Medical Supply Chain division, awarded a firm fixed-price delivery order valued at $47,732.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which authorizes the issuance of...
- The Defense Logistics Agency awarded a delivery order valued at $1,002.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a continuation of the company's substantial role as a prime vendor within the DLA's pharmaceutical supply network. The award carries no set-aside designation, allowing DMS...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATWNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,496.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 mL syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, operates under a firm fixed-price structure with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against all qualified vendors. The product will be delivered to Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition vehicle established to provide pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. serves as a critical regional pharmaceutical supplier under the PPV-G GEN V initiative, which authorizes the company to supply branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare operations globally. The company's single-award IDC, valued at $499.999 billion with a completion date of December 31, 2036, consists of a 30-month base period with three 30-month option periods. As a registered federal contractor since 2001, DMS Pharmaceutical Group has demonstrated substantial performance on numerous DLA-funded delivery orders across diverse therapeutic categories, establishing itself as a reliable supplier for specialized pharmaceutical requirements within the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.5k | 10/20/25 |